Organovo (ONVO) Competitors $0.33 -0.02 (-5.71%) (As of 12:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ONVO vs. SPRB, CYTH, ENLV, UBX, MEIP, FNCH, BFRG, NNVC, FBRX, and CGTXShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Spruce Biosciences (SPRB), Cyclo Therapeutics (CYTH), Enlivex Therapeutics (ENLV), Unity Biotechnology (UBX), MEI Pharma (MEIP), Finch Therapeutics Group (FNCH), Bullfrog AI (BFRG), NanoViricides (NNVC), Forte Biosciences (FBRX), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Organovo vs. Spruce Biosciences Cyclo Therapeutics Enlivex Therapeutics Unity Biotechnology MEI Pharma Finch Therapeutics Group Bullfrog AI NanoViricides Forte Biosciences Cognition Therapeutics Spruce Biosciences (NASDAQ:SPRB) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend SPRB or ONVO? Spruce Biosciences currently has a consensus target price of $4.00, suggesting a potential upside of 724.06%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Organovo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SPRB or ONVO? In the previous week, Organovo had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Organovo and 0 mentions for Spruce Biosciences. Organovo's average media sentiment score of 0.80 beat Spruce Biosciences' score of -0.07 indicating that Organovo is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral Organovo Positive Which has better valuation & earnings, SPRB or ONVO? Organovo has lower revenue, but higher earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$10.09M1.99-$47.92M-$0.94-0.52Organovo$110K46.11-$14.67M-$1.06-0.31 Is SPRB or ONVO more profitable? Spruce Biosciences has a net margin of -555.23% compared to Organovo's net margin of -12,176.70%. Spruce Biosciences' return on equity of -62.10% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Organovo -12,176.70%-249.28%-159.50% Do insiders & institutionals believe in SPRB or ONVO? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, SPRB or ONVO? Spruce Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Does the MarketBeat Community believe in SPRB or ONVO? Organovo received 157 more outperform votes than Spruce Biosciences when rated by MarketBeat users. However, 60.00% of users gave Spruce Biosciences an outperform vote while only 47.80% of users gave Organovo an outperform vote. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3960.00% Underperform Votes2640.00% OrganovoOutperform Votes19647.80% Underperform Votes21452.20% SummarySpruce Biosciences beats Organovo on 12 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07M$2.97B$5.09B$8.79BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-0.3118.1093.0914.02Price / Sales46.11281.591,220.6787.41Price / CashN/A169.3839.4936.27Price / Book1.384.406.936.33Net Income-$14.67M-$41.63M$118.83M$225.71M7 Day Performance-9.34%-5.26%-1.74%-0.58%1 Month Performance-28.57%-7.03%-3.60%1.49%1 Year Performance-73.81%25.64%31.91%27.23% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovo0.6793 of 5 stars$0.33-5.7%N/A-72.7%$5.07M$110,000.00-0.3120Analyst ForecastNews CoverageSPRBSpruce Biosciences2.9764 of 5 stars$0.49-0.9%$4.00+724.1%-64.0%$20.05M$10.09M0.0020Gap DownENLVEnlivex Therapeutics3.075 of 5 stars$0.93-5.2%$6.00+548.6%-42.9%$19.81MN/A0.0070News CoverageGap UpCYTHCyclo Therapeutics2.7699 of 5 stars$0.69-3.0%$0.95+38.2%-47.9%$19.78M$1.08M0.009News CoverageGap DownUBXUnity Biotechnology3.6114 of 5 stars$1.16-0.9%$8.00+590.3%-42.1%$19.53M$240,000.000.0060MEIPMEI Pharma4.1926 of 5 stars$2.77-1.1%$7.00+152.7%-50.5%$18.45M$65.30M-0.40100FNCHFinch Therapeutics GroupN/A$11.43-0.2%N/A+216.3%$18.40M$110,000.000.00190BFRGBullfrog AIN/A$2.10+4.0%N/A-36.3%$18.29M$60,000.000.004Gap UpNNVCNanoViricidesN/A$1.31-1.5%N/A+15.8%$18.27MN/A-1.7420Analyst DowngradePRPHProPhase Labs3.2606 of 5 stars$0.76-0.1%$11.00+1,338.8%-82.8%$18.25M$44.38M0.00130FBRXForte Biosciences3.6486 of 5 stars$12.49-7.8%$23.58+88.8%+69,372.9%$18.24MN/A-0.685Analyst RevisionNews CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies Spruce Biosciences Competitors Cyclo Therapeutics Competitors Enlivex Therapeutics Competitors Unity Biotechnology Competitors MEI Pharma Competitors Finch Therapeutics Group Competitors Bullfrog AI Competitors NanoViricides Competitors Forte Biosciences Competitors Cognition Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONVO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
